公开(公告)号：US20130095161A1

公开(公告)日：2013-04-18

申请号：US13645941

申请日：2012-10-05

Applicant: Lukas Bluecher ,  Michael Milbocker

Inventor： Lukas Bluecher ,  Michael Milbocker

IPC: A61K31/785

CPC classification number: A61K31/785 ,  C08G18/10 ,  C08G18/12 ,  C08G18/4277 ,  C08G18/6484 ,  C08G18/66 ,  C08G18/6633 ,  C08G18/6666 ,  C08G18/755 ,  C08G18/3206 ,  C08G18/4837

Abstract: The present disclosure relates to compositions A composition comprising a polymerization product of an anionic polysaccharide, a diisocyanate, and a linker, wherein the linker comprises i) an ether group, an ester group, or a combination thereof and, ii) a chain extender comprising a hydroxyl group, a thiol group, an amine group, or a combination thereof. The disclosure further relates to medical devices comprising the aforementioned compositions, and to methods of using the compositions and devices. More particularly, the compositions, devices and methods described herein are useful for preventing protein adhesions in vivo, particularly the Vroman effect.

Abstract translation: 本公开内容涉及组合物包含阴离子多糖，二异氰酸酯和接头的聚合产物的组合物，其中所述连接体包含i）醚基团，酯基团或其组合，和ii）扩链剂，其包含 羟基，硫醇基，胺基或其组合。 本公开还涉及包含上述组合物的医疗装置，以及使用组合物和装置的方法。 更具体地，本文所述的组合物，装置和方法可用于预防体内蛋白质粘连，特别是Vroman效应。

公开(公告)号：US20130052236A1

公开(公告)日：2013-02-28

申请号：US13597821

申请日：2012-08-29

Applicant: Joerg Tessmar ,  Eva Esser ,  Lukas Bluecher ,  Michael Milbocker

Inventor： Joerg Tessmar ,  Eva Esser ,  Lukas Bluecher ,  Michael Milbocker

IPC: A61K9/00 ,  A61F13/00 ,  A61K38/44

CPC classification number: A61L31/10 ,  A61L31/022 ,  A61L31/048 ,  A61L31/06 ,  C08L67/04 ,  C08L5/04

Abstract: The present disclosure provides a medical assembly comprising a surgical barrier aspect comprising polylactic acid, and a hydrophilic mucoadhesive aspect, wherein the surgical barrier aspect is provided on a first side of the assembly and the mucoadhesive aspect is provided on a second side of the assembly. The disclosure also relates to a medical assembly comprising a surgical barrier aspect, a short term mucoadhesive aspect, an intermediate term protein polymerization adhesive aspect, and a long term tissue ingrowth implant localization aspect. The aforementioned medical assemblies may be provided as layered sheet structures. Also provided are methods for preparing a medical assembly.

Abstract translation: 本公开提供了一种医疗组件，其包括包含聚乳酸的外科屏障方面和亲水性粘膜粘附方面，其中手术屏障方面设置在组件的第一侧上，并且粘膜粘附方面设置在组件的第二侧上。 本公开还涉及包括手术屏障方面，短期粘膜粘附方面，中间术语蛋白质聚合粘合剂方面和长期组织向内生长定位方面的医疗组合件。 上述医疗组件可以设置为层状片结构。 还提供了用于制备医疗组件的方法。

公开(公告)号：US20120039959A1

公开(公告)日：2012-02-16

申请号：US13211226

申请日：2011-08-16

Applicant: Joerg TESSMAR ,  Eva Esser ,  Thomas Reintjes ,  Lukas Bluecher ,  Michael T. Milbocker

Inventor： Joerg TESSMAR ,  Eva Esser ,  Thomas Reintjes ,  Lukas Bluecher ,  Michael T. Milbocker

IPC: A61K9/00 ,  A61P43/00 ,  A61K47/36

CPC classification number: A61L27/20 ,  A61L27/54 ,  A61L31/042 ,  A61L31/16 ,  C08L5/04

Abstract: Described are mono- and bi-layer alginate post-surgical anti-adhesion barriers with tailored absorption profiles and non-migrating characteristics. Muco-adhesive properties of alginates in their solid state are used to localize the device, and lubricious properties of alginates in their liquid state are used to mitigate adhesion formation during wound healing. In addition, the design of the implant can be selected such that the crosslinking agent is released from the device under specific conditions and the absorbance profile modified. A medicinal agent may optionally be incorporated.

Abstract translation: 描述了具有定制的吸收曲线和非迁移特性的单层和双层藻酸盐后手术抗粘连屏障。 使用固态藻酸盐的粘稠粘合性能来定位装置，并且使用其液态藻酸盐的润滑性能来减轻伤口愈合期间的粘附形成。 此外，可以选择植入物的设计，使得交联剂在特定条件下从装置释放并且修改吸光度分布。 可以任选地并入药剂。

公开(公告)号：US20090060978A1

公开(公告)日：2009-03-05

申请号：US12199760

申请日：2008-08-27

Applicant: Lukas Bluecher

Inventor： Lukas Bluecher

IPC: A61K9/70 ,  A61K38/18

CPC classification number: A61L31/041 ,  A61L31/06 ,  C08L67/04 ,  C08L71/02

Abstract: Resorbable lactide polymer micro-membranes are disclosed. The micro-membranes are constructed of polylactide resorbable polymers, which are engineered to be absorbed into the body relatively slowly over time in order to reduce potential negative side effects. The membranes are formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about O.300 mm. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be preshaped with relatively thick portions, and can be stored in sterile packages.

Abstract translation: 公开了可再吸收的丙交酯聚合物微膜。 微膜由聚丙交酯可吸收聚合物构成，其被设计成随着时间相对缓慢地吸收到身体中以减少潜在的负面副作用。 膜被形成为具有非常薄的厚度，例如，厚度在约0.010mm和约O.300mm之间。 膜可以从具有相对高粘度性质的聚丙交酯聚合物挤出，可以用相对较厚的部分预成型，并且可以储存在无菌包装中。

公开(公告)号：US20100114328A1

公开(公告)日：2010-05-06

申请号：US12498291

申请日：2009-07-06

Applicant: Michael T. Milbocker ,  Lukas Bluecher

Inventor： Michael T. Milbocker ,  Lukas Bluecher

IPC: A61F2/02 ,  A61B19/08

CPC classification number: A61F13/023 ,  A61B17/0057 ,  A61B17/085 ,  A61B2017/00004 ,  A61B2017/00243 ,  A61B2017/00597 ,  A61B2017/00893 ,  A61B2090/0816 ,  A61L31/148

Abstract: A resorbable thin membrane is applied over a treatment site before a treatment is applied over the resorbable thin membrane to the site. In a particular implementation, a resorbable thin membrane is adhesively applied over a treatment site of tissue before a treatment is conducted onto the tissue whereby the treatment is performed through the resorbable thin membrane. The treatment can be an incision that is made through both the resorbable membrane and into or through the tissue.

Abstract translation: 在可再吸收的薄膜上施用处理之前，将可再吸收的薄膜施加在处理部位上。 在具体实施方案中，在对组织进行处理之前，将可再吸收的薄膜粘附施加在组织的处理部位上，由此通过可再吸收的薄膜进行处理。 治疗可以是通过可再吸收的膜并通过组织进入的切口。

公开(公告)号：US20100266663A1

公开(公告)日：2010-10-21

申请号：US12767716

申请日：2010-04-26

Applicant: Christopher J. Calhoun ,  Lukas Bluecher

Inventor： Christopher J. Calhoun ,  Lukas Bluecher

IPC: A61F2/00

CPC classification number: A61L27/18 ,  A61F2/0063 ,  A61L31/06 ,  C08L67/04

Abstract: A prosthesis for repairing a hernia includes an adhesion-resistant biodegradable region and an opposing tissue-ingrowth biodegradable region. When the prosthesis is implanted into the patient, the adhesion-resistant biodegradable region covers a fascial defect of the hernia, and the tissue-ingrowth biodegradable region is located above the adhesion-resistant biodegradable region while being exposed substantially only to the host's subcutaneous tissue layer. This orientation allows the tissue-ingrowth biodegradable region to become firmly incorporated with the host's body tissue. The adhesion-resistant biodegradable region faces the internal organs and decreases the incidence of adhesions and/or bowel obstruction.

Abstract translation: 用于修复疝的假体包括耐粘附的生物可降解区域和相对的组织向内生长可降解区域。 当将假体植入患者体内时，耐粘附的生物可降解区域覆盖疝气的筋膜缺损，并且组织向内生长可降解区域位于耐粘附的生物可降解区域之上，同时基本上仅暴露于宿主的皮下组织层 。 该方向允许组织向内生长可降解区域与主体的身体组织牢固地结合。 耐粘附的生物可降解区域面向内部器官并降低粘连和/或肠梗阻的发生率。